Jacob E. Hartman

Jacob E. Hartman is a patent litigation attorney at Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C., where his practice encompasses a broad range of complex commercial and intellectual property disputes. His experience spans various technology areas, with a notable focus on generic pharmaceuticals, particularly biologics, as evidenced by his role as lead counsel for Regeneron Pharmaceuticals, Inc. in patent litigation concerning its Eylea® product. He also possesses experience with high-technology cases, including a matter involving fiber optic equipment before the U.S. International Trade Commission.

Mr. Hartman primarily represents plaintiffs in patent infringement matters. His tracked appearance for Regeneron Pharmaceuticals, Inc. against Sandoz Inc. (part of the broader In re Aflibercept Patent Litigation MDL) highlights his work for brand-name pharmaceutical companies defending their intellectual property against biosimilar manufacturers. Beyond pharmaceutical litigation, he successfully represented a complainant in an International Trade Commission investigation, securing a Final Initial Determination of violation and a recommended general exclusion order for high-density fiber optic equipment.

While his firm, Kellogg Hansen, has a deep bench of appellate understanding in patent law and lawyers who have argued patent matters in the Federal Circuit, specific regular appearances by Mr. Hartman in PTAB or IPR proceedings are not explicitly detailed in publicly available information.

Mr. Hartman earned his J.D., magna cum laude, from the University of Pennsylvania Law School in 2015, where he also received an MBE from the Perelman School of Medicine. He holds a B.S. from Duke University (2006). Following law school, he served as a law clerk to Judge Kent A. Jordan on the U.S. Court of Appeals for the Third Circuit. He is admitted to practice in Maryland (2015) and the District of Columbia (2017).